ES2186674T3 - Comprimidos de liberacion sostenida que contienen niacina y estuches. - Google Patents

Comprimidos de liberacion sostenida que contienen niacina y estuches.

Info

Publication number
ES2186674T3
ES2186674T3 ES93401681T ES93401681T ES2186674T3 ES 2186674 T3 ES2186674 T3 ES 2186674T3 ES 93401681 T ES93401681 T ES 93401681T ES 93401681 T ES93401681 T ES 93401681T ES 2186674 T3 ES2186674 T3 ES 2186674T3
Authority
ES
Spain
Prior art keywords
kids
tablets
cases
sustained release
release containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93401681T
Other languages
English (en)
Inventor
Victoria A O'neill
Kenneth L Evenstad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kos Pharmaceuticals Inc
Original Assignee
Kos Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25421462&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2186674(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kos Pharmaceuticals Inc filed Critical Kos Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2186674T3 publication Critical patent/ES2186674T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Physical Water Treatments (AREA)
  • Non-Alcoholic Beverages (AREA)

Abstract

LA INVENCION PRESENTA UN METODO TERAPEUTICO PARA EL TRATAMIENTO DE LA HIPERLIPIDEMIA QUE CONSISTE EN ADMINISTRAR A UN PACIENTE HUMANO UNA SOLA DOSIS DIARIA DE UN TIPO DE DOSIS DE LIBERACION PROLONGADA DE NIACINA, DE TAL MODO QUE SE ELIMINA DE MANERA EFECTIVA LA SINTESIS NOCTURNA DEL COLESTEROL.
ES93401681T 1992-06-29 1993-06-29 Comprimidos de liberacion sostenida que contienen niacina y estuches. Expired - Lifetime ES2186674T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/905,785 US5268181A (en) 1989-04-13 1992-06-29 Method of using niacin to control nocturnal cholesterol synthesis

Publications (1)

Publication Number Publication Date
ES2186674T3 true ES2186674T3 (es) 2003-05-16

Family

ID=25421462

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93401681T Expired - Lifetime ES2186674T3 (es) 1992-06-29 1993-06-29 Comprimidos de liberacion sostenida que contienen niacina y estuches.

Country Status (7)

Country Link
US (1) US5268181A (es)
EP (3) EP1688143A3 (es)
AT (1) ATE227128T1 (es)
DE (1) DE69332463T2 (es)
DK (1) DK0577504T3 (es)
ES (1) ES2186674T3 (es)
PT (1) PT577504E (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721221A (en) * 1991-03-08 1998-02-24 Regents Of The University Of Minnesota Lowering blood cholesterol levels using water soluble cellulose ethers
DE4329794C2 (de) * 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
EP2319513A1 (en) * 1993-09-20 2011-05-11 Abbott Respiratory LLC Nicotinic acid compositons for treating hyperlipidemia and related methods therefor
US20080045573A1 (en) * 1993-09-20 2008-02-21 Bova David J Methods and Sustained Release Nicotinic Acid Compositions for Treating Hyperlipidemia
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6406715B1 (en) * 1993-09-20 2002-06-18 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6746691B2 (en) * 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
AU5787996A (en) * 1995-04-19 1996-11-07 Lipoprotein Technologies, Inc. Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
ES2191706T3 (es) * 1995-06-07 2003-09-16 Pfizer Derivados de tetrahidro-isoquinolinil-6-il amida del acido bifenil-2-carboxilico, su preparacion y su uso como inhibidores de la proteina de transferencia de trigliceridos microsomal y/o secrecion de apolipoproteina b (apo b).
US7179486B1 (en) * 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
US6469035B1 (en) * 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
NZ520176A (en) * 1997-07-31 2005-02-25 Kos Life Sciences Inc Combinations of HMG-CoA reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
UA77660C2 (en) * 2000-10-03 2007-01-15 Compositions and methods for reducing plasma lipoprotein a level in human
US7052706B2 (en) * 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
AU2005305086A1 (en) * 2004-11-05 2006-05-18 Arena Pharmaceuticals, Inc. Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists
US20080096979A1 (en) * 2004-11-08 2008-04-24 Rubicon Research Pvt. Ltd. Aqueous Pharmaceutical Coating
FR2878748B1 (fr) * 2004-12-07 2007-03-09 Arrow Generiques Soc Par Actio Formule de comprimes permettant une liberation prolongee d'indapamide apres administration par voie orale et procede de preparation
JP2008538277A (ja) * 2005-02-18 2008-10-23 アリーナ ファーマシューティカルズ， インコーポレイテッド 脂質関連障害の治療用の組成物および方法
US20070053930A1 (en) * 2005-09-07 2007-03-08 Bebaas, Inc. Combination therapy for treatment of high cholesterol
CA2569776A1 (en) * 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation
WO2008100249A1 (en) * 2007-02-13 2008-08-21 Kos Life Sciences, Inc. Low flush niacin formulation
EP2114151A4 (en) * 2007-03-01 2010-03-17 Concourse Health Sciences Llc INOSITOL NIACINATE ISOMERS AND USES THEREOF
CL2008000684A1 (es) 2007-03-09 2008-08-01 Indigene Pharmaceuticals Inc Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
KR100836960B1 (ko) 2007-09-07 2008-06-10 주식회사 서울제약 새로운 나이아신 제어방출형 제제
BRPI0913425A2 (pt) * 2008-06-02 2015-11-24 Reddys Lab Ltd Dr formulações de niacina com liberação modificada
WO2010010579A1 (en) * 2008-07-19 2010-01-28 Lupin Limited Multiple unit dosage form of niacin
WO2013052117A1 (en) 2011-10-05 2013-04-11 Golini Jeffrey M Choline composition
US20140113939A1 (en) * 2012-10-22 2014-04-24 Abbott Laboratories Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
JPS5031022A (es) * 1973-05-29 1975-03-27
US4166902A (en) * 1974-10-14 1979-09-04 Paolo Ferruti High polymers containing nicotinic acid, process for their preparation and their use
US4568547A (en) * 1979-08-30 1986-02-04 Herschler R J Solid pharmaceutical compositions comprising MSM and their production
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4457907A (en) * 1982-08-05 1984-07-03 Clear Lake Development Group Composition and method for protecting a therapeutic drug
FR2535202B1 (fr) * 1982-11-03 1985-08-09 Fabre Sa Pierre Comprimes de theophylline a liberation controlee et leur procede de fabrication
US4749575A (en) * 1983-10-03 1988-06-07 Bio-Dar Ltd. Microencapsulated medicament in sweet matrix
US4680323A (en) * 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
NL8600050A (nl) * 1986-01-13 1987-08-03 Sanico Nv Farmaceutisch preparaat met vertraagde afgifte van het werkzame bestanddeel en werkwijze voor de bereiding er van.
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US4795642A (en) * 1986-05-01 1989-01-03 Pharmacaps, Inc. Gelatin-encapsulated controlled-release composition
US4708834A (en) * 1986-05-01 1987-11-24 Pharmacaps, Inc. Preparation of gelatin-encapsulated controlled release composition
US4752479A (en) * 1986-05-27 1988-06-21 Ciba-Geigy Corporaton Multi vitamin and mineral dietary supplement with controlled release bioavailable iron
US5110940A (en) * 1987-02-25 1992-05-05 Bristol-Myers Company Antihypercholesterolemic tetrazole compounds
US4950689A (en) * 1987-03-31 1990-08-21 Yang Robert K Pectin delivery system
JPS63310827A (ja) * 1987-06-15 1988-12-19 Sanwa Kagaku Kenkyusho Co Ltd ニコチン酸誘導体を主剤とする徐放性製剤
US5023245A (en) * 1987-11-10 1991-06-11 Hauser-Kuhrts, Inc. Improved niacin formulation
US4965252A (en) * 1988-06-28 1990-10-23 Hauser-Kuhrts, Inc. Cholesterol-lowering combination compositions of guar gum and niacin
US4911917A (en) * 1988-06-28 1990-03-27 Hauser-Kuhrts, Inc. Cholesterol-lowering combination comopsitions of magnesium salt and niacin
US5116610A (en) * 1987-12-29 1992-05-26 The Procter & Gamble Company Compositions for treating hypercholesterolemia
US5030653A (en) * 1988-03-30 1991-07-09 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic compounds and compositions
US5049696A (en) * 1988-04-11 1991-09-17 Merck & Co., Inc. Antihypercholesterolemic compounds
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
US5034528A (en) * 1988-07-27 1991-07-23 North Carolina Central University Compositions for the control of hyperlipidemia
US5011947A (en) * 1988-08-25 1991-04-30 Bristol-Myers Antihypercholesterolemic alkylene compounds
US4920123A (en) * 1988-10-21 1990-04-24 Beyer Jr Karl H Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals
US5110817A (en) * 1988-10-21 1992-05-05 Beyer Jr Karl H Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals
US4920115A (en) * 1988-12-28 1990-04-24 Virginia Commonwealth University Method of lowering LDL cholesterol in blood
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5002774A (en) * 1989-06-08 1991-03-26 Erbamont, Inc. Sustained release pharmaceutical tablet
US5010105A (en) * 1989-06-09 1991-04-23 Merck & Co., Inc. Antihypercholesterolemic compounds

Also Published As

Publication number Publication date
DE69332463D1 (de) 2002-12-12
EP0577504A1 (en) 1994-01-05
EP0577504B1 (en) 2002-11-06
PT577504E (pt) 2003-03-31
DK0577504T3 (da) 2003-03-17
DE69332463T2 (de) 2003-07-10
EP1310253A1 (en) 2003-05-14
EP1688143A2 (en) 2006-08-09
EP1688143A3 (en) 2009-11-11
US5268181A (en) 1993-12-07
ATE227128T1 (de) 2002-11-15

Similar Documents

Publication Publication Date Title
ES2186674T3 (es) Comprimidos de liberacion sostenida que contienen niacina y estuches.
NO306235B1 (no) Anvendelse av et legemiddel for behandling av artritt
EP0581226A3 (en) Light-curing reactor and small light irradiation device for dental use.
PL297747A1 (en) Prolonged action pharmaceutical dosage forms
WO1994027589A3 (en) Antidepressant dosage form
FR2653338B1 (fr) Formulation pour des pansements a liberation prolongee de medicament et son utilisation.
PT100973A (pt) Dispositivo e composicoes farmaceuticas para a administracao de melatonina por via transdermica
DK0547952T3 (da) Anvendelse af modafinil til fremstilling af et antiisskæmisk lægemiddel
DE69219726T2 (de) Intravenöse dosierungen überwachende vorrichtung
DE69326539T2 (de) Zytotoxische arzneimittel therapie
DE69312501T2 (de) Zahnseidenabgabevorrichtung und Applikator
NO910080L (no) Svelgbare doseringsenheter omfattende kolloidalt vismut-subsitrat.
GB2270262B (en) Wheeliebin freshener and disinfector
GB9302004D0 (en) A device for protacted release of active substances,perfumes and similar volatile substances
NO179504C (no) Legemiddel i form av en tablett inneholdende diritromycin
DE69231263T2 (de) Calcitonin enthaltende pharmazeutische Zusammensetzungen
ITMI920261U1 (it) Vaporizzatore per scopi medicali e cosmetici
IL117465A (en) Use of certain cystine derivatives for the preparation of a medicament for the treatment of restenosis
GB9508938D0 (en) Medication dosage reminder device
KR940005106U (ko) 한방용 약액 포장장치
NO920031D0 (no) Synergistisk middel for terapeutisk behandling, preparat inneholdende nevnte middel, og anvendelse av middelet for fremstilling av et legemiddelpreparat
DK86093D0 (da) Praeparat til medikamentel behandling for tandlaegebrug mod lidelserne tandkoedsbetaendelse og tandnervebetaendelse
SI0825859T1 (en) Use of forskolin or extracts containing it in the manufacture of a medicament for the treatment of alcohol addiction
SE9201261D0 (sv) Anordning foer medicineringspaaminnelse
GB9507677D0 (en) Pharmaceutical formulation and dose